Aug 11, 2020
Cardiff Oncology Announces Second Quarter 2020 Results and Highlights
Jun 18, 2020
Linnaeus Therapeutics Granted U.S. FDA Fast Track Designation for LNS8801 for the Treatment of Patients with Metastatic or Unresectable Melanoma Who Have Progressed on Anti-PD-1/L1 Therapy
Jun 16, 2020
Oncologie Announces Key Updates and Planned Activities for its Clinical Programs and RNA-based Biomarker Platform
Jun 11, 2020
Scopus BioPharma Licenses Novel Immuno-Oncology Gene Therapy Drug from City of Hope, a Cancer Center in Los Angeles, California
Jun 09, 2020
Cardiff Oncology Announces Expanded Access Program for Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer as Follow-On to Fast Track Designation
May 31, 2020
Innovent Biologics Announced the Results of the Phase 1b Clinical Study of TYVYT® (Sintilimab Injection) in Combination with IBI305 (Bevacizumab Biosimilar) in the Treatment of Advanced Hepatocellular Carcinoma
May 30, 2020
Guardant360 test results may provide prognostic information beyond the detection of actionable biomarkers for ALK-rearranged NSCLC patients
May 29, 2020
Cardiff Oncology Data Continues to Demonstrate Efficacy of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer Presented at ASCO
May 28, 2020
Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer
May 26, 2020
Beacon Targeted Therapies Launches Its Latest Clinical Trial and Drug Database Solution - Beacon Gene Therapy
May 19, 2020
Cardiff Oncology Announces Private Placement Investment by Board of Directors and Chief Executive Officer
May 15, 2020
Ascentage Pharma to Present Six Abstracts at 2020 AACR Annual Meeting
May 15, 2020
Mirati Therapeutics To Present Preclinical Data From Investigational Pipeline Of Novel Therapeutics At 2020 American Association For Cancer Research Virtual Annual Meeting II
May 15, 2020
IDEAYA Biosciences Announces AACR Abstracts for IDE196 Targeting GNAQ/11 Tumors and Preclinical MAT2A Synthetic Lethality Program
May 13, 2020
Cardiff Oncology Enters Agreement with PoC Capital to Fund Phase 2 Clinical Trial of Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer (mCRC)
May 12, 2020
Non-Small Cell Lung Cancer (NSCLC) Market Forecasts to 2030: A Comprehensive Insight
May 06, 2020
FDA Approves First Targeted Therapy to Treat Aggressive Form of Lung Cancer
May 06, 2020
Novartis announces FDA approval of MET inhibitor Tabrecta(TM) for metastatic non-small cell lung cancer with METex14
Apr 28, 2020
BioEclipse Receives FDA Clearance of Investigational New Drug Application for CRX100
Apr 09, 2020
Bolt Biotherapeutics Appoints Edith Perez, M.D., as Chief Medical Officer